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This review covers new mechanistic information spanning the past 10 years relevant to normal
and abnormal thyroid growth and function that may assist in the risk assessment ofchemicals
inducing thyroid follicular cell neoplasia. Recent studies have shown that thyroid regulation
occurs via a complex interactive networkmediated through seral different mesengersyems.
Increasedthyroid-stimulating hormone (TSH) levelsactivatethesignal transduction pathways to
stimulate growth and differentiation oftheflhllicular cell. Theimportant role ofTSH in growth
as well as in function helps to explain how disruptions in thethyroid-pitui"ty axis may influ-
encethyroid neoplasiain rodents. Newin igios thatcouple mechanistic studieswith infor-
mation from animal cancer bioassays (e.g., sulfametbazine studies) confirm the linkage between
prolonged disruption ofthethyroid-pituitary axis andthyroidneoplaia. Newinitiationlpromo-
tion studies in rodents also support the concept that chronic stimulation ofthe thyroid induced
by goitrogens can result in thyroid tumors. Some ofthese studies confirm previoussuggesions
regarding theimportance ofchemicallyinduced thyroid peroxidase inhibition andtheinhibition
of3,3',5,5'-tetraiodothyronine (T4, thyroxine) deiodina on ruption ofthe thyroid-pitu-
itaryaxis leading tothyroidneoplasia. Somecomparativephysiologic andmechanisticdatahigh-
light certain differences between rodents and humans that could be expected to confer an
increased vulnerability ofrodents to chronic hypersecretion ofTSH. New data from epidemio-
logicand molecular genetic studies inhumans contribute firther to an understanding ofthyroid
neoplasia.Acuteexposuretoionizingradiation, especiallyinchildhood, remains the onlyverified
cause ofthyroid carcinogenesis inhumans. Iodine deficiencystudies as awhole remainincondu-
sive, even though several new studies in humans examine the role ofdietaryiodinedeficiency in
thyroid cancer. Specific alterations in gene expression have been identified in human thyroid
neoplasia, linked to tumorphenotype, and thus oncogene activation and tumor-suppressor gene
inactivation may also be factors in the development and progression ofthyroid cancer in
humans. An analysis by the U.S. EPA Risk Assessment Forum, prepared as a draft report in
1988 and completed in 1997, focused on the use ofa threshold for risk assessment ofthyroid
follicular tumors. New studies, involving several chemicals, provide fiuther support that there
will be no antithyroid activity until critical intracellular concentratons are reached. Thus, for
chemicallyinducedthyroidneoplasialinked to disruptions in thethyroid-pituitaryaxis, apracti-
cal thresholdfor thyroidcancerwouldbeexpected. Moreinformation onthyroidautoregulation,
the role ofoncogene mutations andgrowthfacrs, andstudiesdirectylinkingpersistendyhigh
TSH levels with the sequential celular development ofthyroid foicular cell neoplasia would
provide further confirmation. Key works: growth factors, sigal transduction, thyroid adenoma,
thyroid carcinogens, thyroid carcinoma, thyroid hormone metabolism, thyroid peroxidase, thy-
roid-stimulatinghormone. EnvironHealhPespet106:427436 (1998). [Online24June 1998]
hp://ebpnetl.nkehs.nib.govldocs/1998/106p427-36bard/abstrt~html
Most risk assessment issues involving the
thyroid concern the role ofprolonged eleva-
tion ofcirculating thyroid-stimulating hor-
mone (TSH) levels in the development of
follicular cell neoplasia in laboratory ani-
mals and the appropriate procedures for
extrapolation of these results to humans. A
Technical Panel of the U.S. EPA Risk
Assessment Forum examined this issue and
concluded in a 1988 draft report that,
under certain circumstances, thyroid follic-
ular cell tumors develop through linked
steps beginning with interference in thy-
roid-pituitary status. When there is no
direct interaction of the chemical with
DNA, the EPA Technical Panel concluded
that thyroid follicular neoplasia involves a
nonlinear dose-response process and
would not develop unless there is pro-
longed interference with the thyroid-pitu-
itary feedback mechanisms. The mechanis-
tic information assembled in the 1988
draft was published in 1989 (1). Into
1997, the EPA RiskAssessment Forum has
continued to develop a science policy state-
ment for assessing risk ofthyroid follicular
cell neoplasia, requiring an update of the
pertinent literature as part ofthat process.
Since the EPA report on thyroid follicu-
lar cell carcinogenesis was published (1),
more than 600 papers on thyroid function,
regulation, carcinogenesis, and epidemiolo-
gy have appeared in the literature. Recent
studies on regulation of the thyroid gland
and thyroid follicular cell neoplasia present a
broad array of new data, which add depth
and complexity to the information available
in 1988 on this fundamental biological
process. These studies provide information
on growth factors and messenger systems,
the neuroendocrine control of TSH secre-
tion, the intrinsic heterogeneity in follicular
cell populations with regard to proliferative
potential, and new data on thyroid cancer in
both rodents and humans, including molec-
ular genetic and cytogenetic aspects. This
review of the new publications highlights
selected information that is considered most
relevant to the mechanisms of normal and
abnormal thyroid growth and function and
the action ofchemicals thereon.
Thyroid Regulation
Numerous recent studies point to the conclu-
sion that the physiological regulation of thy-
roid cell growth and function involves a com-
plex interactive network of trophic factors
(endocrine, paracrine, and autocrine). The
effects ofthese factors are mediated through a
number of different second messenger sys-
tems. It is well established that TSH is the
main growth factor forthyroidcells, maintain-
ing the differentiated state ofthe thyroid and
controlling thyroid hormone secretion. Other
growth regulators involved in the complex
web includeinsulin/insulinlike growthfactor-I
(IGF-I), epidermal growth factor (EGF), basic
fibroblast growth factor (bFGF), transforming
growth factorP3 (TGF-P), and an endogenous
iodidedependent mechanism (2,3).
TSH exerts its action on thyroid follicu-
lar cellsvia receptor sites, restricted mainly to
the basal membranes offollicle cells (4). The
advent ofrecombinant DNA technology has
led to the cloning of the TSH receptor of
both rat (5) and human thyroid (6-9). The
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TSH receptor is a plasma membrane site
able to bind G (guanine nucleotide-binding)
protein for signal transduction (8). G pro-
tein activation by the TSH receptor appears
to be a highly complex effector system
involving all four G protein families (10).
The gene for the TSH receptor is virtually
constitutive in the thyroid cell, occurring far
along the pathway of transformation, as
demonstrated by persistent expression in
normal thyroid tissue as well as in differenti-
ated thyroid tumors, but not undifferentiat-
ed carcinoma (11). Current models indicate
that the human TSH receptor is aheptaheli-
cal glycoprotein molecule with an extremely
large extracellular domain at the N-termi-
nus, a transmembrane/intracellular region
consisting ofseven intramembrane helices
connected by three alternating intracellular
and extracellular loops, and an intracellular
tail at the carboxyl terminus (12-14). The
extracellular domain is the ligand-binding
site, its amino acid sequence and structure
conferring a high specificity for recognition
and binding ofTSH, distinguishing it from
other G protein-coupled receptors. It is
thought that the three extracellular loops
help the ligand to fit to the tertiary struc-
ture, while the intramembrane and intracel-
lular segments appear to be critical for signal
transduction. Available evidence indicates
that the overall conformation of the TSH
receptor in rats is probably the same as in
humans, there being about 90% homology
in the amino acid sequence of the rat and
human receptors (6,7,9).
TSH, through activation ofits receptor,
has been shown to stimulate more than one
signal transduction pathway in the regula-
tion of both growth and differentiated
function. Each pathway may be related to
specific cellular events. The main effector
ofTSH on proliferation and differentiation
in a variety of species, humans and rats
included, is the cAMP signal transduction
pathway, that is, the cascade involving acti-
vation of adenylate cyclase resulting in
cAMP generation (15,16). The binding of
TSH to its receptor is believed to produce a
structural change in the receptor, activating
the G protein to which it is coupled.
Activation involves dissociation of the as
subunit of the G protein (Gsa), in turn
stimulating adenylate cyclase, thus effecting
a rise in cAMP (14).
There is increasing evidence that the
physiological stimulation of thyroid cell
function by TSH is achieved as well by the
phosphatidyl-inositol/Ca2+ (Pi-C) signal
cascade (via a G protein) with activation of
phospholipase C in rat and human thyroid
cells (16-19). [As a species difference, this
apparently does not apply to dog thyroid
cells (20)]. Thus the TSH receptor can
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activate both signaling systems, but with a
different efficacy because, in contrast to the
cAMP pathway, much higher concentra-
tions ofTSH are required to stimulate the
Pi-C phospholipase C cascade (1/). The sig-
naling by these diverse pathways results in a
range of metabolic consequences including
iodine uptake and release, thyroid peroxi-
dase generation, organification of residues
on thyroglobulin, thyroid hormone synthe-
sis and release, and thyroid cell growth and
division (16). In this complex regulatory
network, the TSH-cAMP cascade is func-
tionally responsible for secretion, while the
Pi-C phospholipase C cascade controls
H202 generation and thyroid hormone syn-
thesis (21). It is generally accepted that
cAMP accounts for the mitogenic effect of
TSH, mediated by the activation ofcAMP-
dependent protein kinases (22), although
higher concentrations of TSH and more
prolonged stimulation ofthe cAMP cascade
are necessary to induce cell proliferation
than for expression of differentiated func-
tion (23). cAMP also appears to play a cen-
tral role in iodide uptake and metabolism by
the follicular cell (24,25) and in thyroglobu-
lin and thyroid peroxidase (TPO) gene
expression (26,24.
A third distinct pathway for signal
transduction related to cell growth and pro-
liferation in the thyroid is the hormone-
receptor-tyrosine protein kinase pathway.
Receptors for certain growth factors, such as
EGF and IGF-1, possess an intrinsic protein
tyrosine kinase activity through which those
growth factors appear to act (2,3,15,28).
However, for the thyroid follicular cell this
signal transduction cascade has not been
well defined.
Growth factors also play a key role,
along with TSH, in the complex regulation
of thyroid cell proliferation, but there are
few data yet to explain how these trophic
factors interact with the cell cycle to stimu-
late or inhibit cell division in the thyroid.
There is evidence from the rat cell line
FRTL-5 that both TSH receptor gene
expression and thyroglobulin gene expres-
sion are under the control ofinsulin/IGF-1
at a transcriptional level as well as TSH
(29-31). Similar evidence for a complex
autoregulatory feedback mechanism involv-
ing insulin/IGF-1 operative at several levels
ofinteractive signaling is accumulating for
other primary thyroid cell culture systems
(32,33). Collective datasuggest that a com-
plex interaction between the 1,2-diacyl-
glycerol/protein kinase C (one ofthe bifur-
cating second messenger pathways of the
Pi-C signal cascade) and the adenyl cyclase
signal transduction systems is important in
the regulation of thyroid growth by TSR
and IGF-1 (34). Thus, in rats, dogs, and
humans, insulin/IGF-1 is considered a nec-
essary cofactor for the action of TSH on
follicle cells, synergizing with TSH to
induce thyrocyte proliferation while main-
taining differentiated function (3,35). In
humans, it has been recorded that benign
and malignant thyroid tumors produce
increased levels of IGF-1 (36,34), leading
to the suggestion that emergent adenoma
cells lose their dependence on exogenous
IGF-1 and acquire the capability for
autocrine production ofthis growth factor.
This could result in continued autostimula-
tion of cell replication, allowing thyroid
nodules to become autonomous (38,39).
Other autocrine/paracrine regulators of
thyroid growth, with potent mitogenic
activity for thyroid cells demonstrable in
vitro, include EGF and bFGF. EGF is syn-
thesized within the thyroid gland and
inducesproliferation in thyroid cells from a
wide range ofspecies at the expense ofde-
differentiation and loss ofspecialized thy-
roid-specific function (40,41). bFGF is
present in human thyroid tissue (42), and
there are stores of FGF in the basement
membrane of follicles in normal adult rat
thyroid (43). EGF has been shown to stim-
ulate the growth and invasion ofdifferenti-
ated human thyroid cancer cells in culture
and in nude mice (44), whereas bFGF
expression increases during thyroid hyper-
plasia in the rat (45).
Transforming growth factor I1 (TGF-
31) is a putative negative regulator ofthy-
roid growth, as studies in normal cell sys-
tems have shown it to inhibitthyrocyte pro-
liferation, including that mediated by TSH
(46-48). Although the actual role ofTGF-
PI in the thyroid is not known, cell culture
and rodent investigations suggest that it is a
limiting autocrine influence on thyroid cell
hyperplasia and cancer growth (49,50). In
one study, TGF-f31 was detected in approx-
imately 50% ofhuman thyroid carcinomas,
but not in adenomas, with a striking corre-
lation being observed between the dual
presence ofTGF-,1 expression and arginine
substitution at codon 61 ofthe H-ras onco-
gene (51). Lazzereschi et al. (52) demon-
strated a significant reduction of TGF-,B
receptor type II mRNA and protein expres-
sion in thyroid carcinomas but found no
reduction in thyroid adenomas. These stud-
ies suggest that escape from the growth-
inhibitory effect of TGF-, may play an
important role in the progression ofhuman
thyroid cancer.
There has also been additional evidence
that iodine is a major mediator ofthyroid
autoregulation, involving numerous
inhibitory actions (53). One of these is a
decrease in cAMP formation in response to
TSH, resulting in an inhibition of all
Volume 106, Number 8, August 1998 * Environmental Health PerspectivesReviews * Thyroid regulation and carcinogenesis
cAMP-mediated stimulatory effects ofTSH
on the thyroid. Excess iodide therefore
exerts a negative control on different thy-
roid parameters, inhibiting iodide uptake
and organification, protein and RNA
biosynthesis, hormone secretion, as well as
paracrine mitogenic activity on endothelial
cells and fibroblasts (54-56). Most ofthese
actions appear to be mediated by an intra-
cellular organified iodine intermediate of
unknown identity. Various derivatives of
arachidonic acid have been proposed as this
putative regulator(s), including the iodinat-
ed eicosanoid, 6-iodolactone (56).
However, this compound had no effect on
TSH-mediated cAMP formation in porcine
follicles (57). Considered to be a more like-
ly candidate is 2-iodohexadecanal (58), a
major iodolipid formed in horse thyroid
when incubated with iodide (59), but
which is also detectable in the thyroid of
other species, including humans and rats.
Transport, Metabolism, and
Excretion ofThyroid
Hormones
Recent studies have confirmed heterogene-
ity in the transport of thyroid hormones
between species. In humans there are three
main carrier proteins which reversibly bind
circulating thyroid hormones, thyroxine-
binding globulin being the major carrier
protein for T4. Transthyretin (formerly
known as thyroxine-binding prealbumin) is
a minor binding protein in humans,
accounting for about 20% of circulating
T4, while albumin, through nonspecific
binding, carries only 10% ofthe circulating
hormone. Collectively these three proteins
transport more than 95% of T3 and T4
hormones in humans (60,61). In rats, a sig-
nificant difference is that thyroxine-binding
globulin occurs only as a postnatal surge,
declining to nondetectable levels by early
maturity at 8 weeks, but reappearing in
senescence (62). Thus, through most of
their lives rats lack one ofthe major carrier
proteins for T4, with transthyretin serving
as the primary plasma transporter. The
binding affinity of transthyretin, however,
is several orders of magnitude lower than
for thyroxine-binding globulin (63).
Likewise, T3 is transported in humans in a
bound state to thyroxine-binding gloubulin
and albumin, but only by albumin in
rodents (63). A primary function of the
transport proteins is believed to be extrathy-
roidal storage of thyroid hormones as a
mechanism to control hormone release,
thereby protecting target tissues from exces-
sive hormone influence (60). By virtue of
the absence ofa majorhigh-affinity binding
protein, this buffering action protecting tar-
gets such as the thyrotrophs ofthe anterior
pituitary would appear to be lower in
rodents. Furthermore, in species in which
T4 binding is limited to transthyretin and
albumin, the proportion of unbound T4 is
greater than it is in humans (63). Coupled
with a considerably shorter half-life for T4
of 12-24 hr in rats compared to 5-9 days
in humans (63), these various interspecies
differences imply a greater predisposition of
rodents to TSH perturbation by chemicals
that influence thyroid status.
There has been much recent progress in
understanding the enzymatic pathways
responsible for metabolism ofT4, T3, and
the inactive T3 analog, reverse T3 (rT3). T4
is secreted by the thyroid but has little bio-
logical activity unless deiodinated to T3.
Two isoenzymes catalyze this 5'-deiodina-
tion reaction: type I 5'-deiodinase (a seleni-
um-containing protein) abundant in liver,
kidney, and thyroid, and type II '-deiodi-
nase (lacking selenium), found primarily in
brain, pituitary, and brown adipose tissue
(64,65). In humans, about 80% ofcirculat-
ing T3 derives from peripheral 5'-mon-
odeiodination of T4, particularly that by
liver and kidney, while 20% ofT3 is secret-
ed by the thyroid (66). In rats, the origin of
circulating T3 is more controversial. Based
on studies with selenium-supplemented and
selenium-depleted rats, Chanoine et al. (65)
suggested that intrathyroidal conversion of
T4 to T3 provides the major source ofT3 in
this species. Comparatively, rat thyroidal
levels oftype I '-deiodinase are the highest
so far reported for anyspecies (66).
Recent studies have also confirmed
that, besides deiodination, conjugations
with either glucuronic acid or sulfate are
significant metabolic pathways for thyroid
hormones in rats (67-69). The enzymes
responsible for glucuronidation of thyroid
hormones are UDP-glucuronoysyltrans-
ferases (UDP-GT) located mainly in the
endoplasmic reticulum of liver cells, but
also found in intestines and kidney. It
appears that there are at least three UDP-
GT isoenzymes involved in rat liver. T4
and rT3 are glucuronidated by types I and
II isoenzyme; T3 is glucuronidated by the
type III isoform (70). The T3 glucuronide
conjugate is excreted in bile, which may
represent a reversible pathway as the conju-
gate is hydrolyzed by intestinal bacteria,
creating an enterohepatic cycle enabling
reabsorption of free T3 (67,71). Evidence
also suggests that there may be a more
effective enterohepatic circulation in
humans than in rats (71).
Sulfate conjugation of thyroid hor-
mones is an alternative metabolic pathway
that enhances enzymatic deiodination and
facilitates their biliary and urinary excre-
tion. The sulfate conjugate ofT3 is rapidly
deiodinated by type I deiodinase through
successive deiodinations of the tyrosyl
(inner) and phenolic (outer) rings (72),
thus releasing iodine into the circulation
for reutilization by the thyroid (73). In
humans, the majority of non-deiodinative
disposal ofT3 occurs via this pathway (74).
Control of TSH Secretion in
the Central Nervous System
At the central nervous system level, recent
work has provided additional information
on the control ofTSH secretion by thyroid
hormones in the anterior pituitary and via
the hypothalamus. A discrete population of
neurons synthesizing thyrotropin-releasing
hormone (TRH), located in the paraventric-
ular nucleus of the hypothalamus, is under
negative feedback regulation by circulating
thyroid hormones (75,76). Some results
suggest that the biosynthesis ofTRH is reg-
ulated by both T andT4 (77), although the
mechanism bywhich T4 plays an inhibitory
role is unknown. The negative feedback of
thyroid hormones on TSH secretion caused
by antithyroid compounds appears to be
exerted mainly at the pituitary level. This is
because the increase in TRH release into
hypophyseal portal blood produced by
propylthiouracil (PTU) is relatively small
(less than 50%) compared to the pro-
nounced increase (up to 20 times at 3
weeks) in serum TSH (78). In humans, new
highly sensitive immunometric assays used
for measurement ofTSH serum concentra-
tions have underscored earlierwork showing
that thyroid hormone negative feedback on
pituitary TSH secretion is mediated mainly
by local generation of T3 within the pitu-
itary from T4 by the 5'-deiodinase enzyme
system (79). Although controversial, some
data suggest that in rats serum T3 has a
greater inhibitory action on TSH secretion
from the pituitary than does serum T4 (80),
at least in the euthyroid or mildly hypothy-
roid states.
Mitogenic Effect of TSH on
Thyroid Tissue
Evidence concerning the mitogenic role of
TSH for thyroidcells in vivohas been further
consolidated over recent years. Studies from
various laboratories using tritiated thymidine
labeling, metaphase arrest techniques for
mitotic index, or immunohistochemical dec-
oration of statin (a non-proliferation-specific
nuclear antigen identifying quiescent Go-
phase cells) show that TSH stimulates, in a
dose- and time-dependent way, the recruit-
ment ofnoncycling Go cells into the cycling
compartment, as well as entry into S-phase
and theentryofG2 cells into mitosis (81).
Recent work has indicated that the nor-
mal rodent (and human) thyroid may have
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an intrinsic heterogeneity in the follicular
cell population regarding the capacity for
proliferative response to TSH. One hypoth-
esis suggests that there are a few subsets of
stemlike follicular cells with a high growth
potential compared to the majority of the
population and that this trait is stable and
heritable (82-85). According to this model,
the clones of cells with extensive prolifera-
tive potential are the origin ofthe adenomas
that develop under conditions of chronic
TSH stimulation (83,84).
As proposed by Studer et al. (86), the
above intrinsic stem cell clone model recon-
ciles earlier kinetic observations (87,88) that
hyperstimulated thyroid attains a plateau
phase ofgrowth orstate of"desensitization,"
with the vast majority of follicular cells
becoming refractory to the mitogenic effects
of increased TSH levels before the emer-
gence ofadenomas. In this model, chronic
TSH stimulation would select preexisting
thyrocyte clones with the greatest prolifera-
tive potential and thus with the greater risk
of neoplastic transformation. An alternative
model for explaining the self-limited nature
ofhyperthyroidism and the development of
hormone-responsive tumors in the chroni-
cally stimulated rat thyroid proposes that
clones of cells escape from the desensitiza-
tion mechanism through mutational events
and natural selection, leading ultimately to
tumor formation (39). Both models agree
that thyroid carcinogenesis involves rare
subsets ofcells responsive to continued TSH
stimulation but differ concerning the origin
of follicular cell heterogeneity. Additional
support for the intrinsic subset concept
and/or the controlling influence ofTSH on
the development ofselected clones ofthy-
roid follicular cells comes from other studies
on cell proliferation (81) and from those
usingtransplantation methodology (89-91).
Rodent Thyroid Cancer
Studies
Although additional bioassays have revealed
newcompounds with thyroid tumor-induc-
ing capability in rodents, such as malon-
aldehyde (92), or have provided stronger
evidence oftumorigenicity as in the case of
sulfamethazine (93,94), the most significant
studies in this area concern the promoting
activity of antithyroid compounds. These
studies have used N-bis(2-hydroxypropyl)-
nitrosamine (DHPN) as the initiating
agent. Promoting activity in the rat has
been confirmed for many antithyroid com-
pounds, including thiourea and potassium
thiocyanate (95), PTU and potassium per-
chlorate (96), 4,4'-methylenebis(N,N-
dimethylbenzenamine) (MDBA) (97), 2,4-
diaminoanisole sulfate (98), sulfadimethox-
ine (99), and phenobarbital (95,100).
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Where thyroidgland and hormone parame-
ters were measured, there were strong corre-
lations between the tumor-promoting activ-
ity on the one hand and increased thyroid
weight, decreased serum T3 and T4 levels,
and increased circulating TSH on the other
(97,98,100). One of these studies (with
MDBA) also linked the increased circulat-
ing level ofTSH with increased numbers of
TSH-positive cells in the anterior lobe of
the pituitary gland (97). The phenobarbital
study was noteworthy in demonstrating a
clear dose-dependent negation ofthyroid
tumor promotion and plasma TSH eleva-
tion by T4 replacement therapy (100). In
investigations where cell proliferative activi-
ty has been determined, the results strongly
support an important role for high serum
levels ofTSH in the early stages ofthyroid
tumorigenesis (99,101).
These tumor promotion studies add
further and consistent support to the
hypothesis that antithyroid compounds
exert effects secondarily on the thyroid
through the chronic stimulation ofpersis-
tently elevated levels ofTSH.
Effects of Specific Chemicals
on the Thyroid-Pituitary Axis
Several recent studies have provided more
quantitative data on the time- and dose-
dependent effects of specific antithyroid
chemicals on thyroid hormone status,
including PTU (102), sulfamethazine
(103), and phenobarbital (100,102). These
studies defined the effects as early but per-
sistent decreases in circulating T3 and T4
levels and a substantial increase in circulat-
ing TSH. Particularly noteworthy are
observations on sulfamethazine, for which
the dose responsiveness for thyroid parame-
ters in rats was studied with 10 dose levels
spanning 3 orders of magnitude (103).
Consistently, the parameters of thyroid
weight and plasma T3, T4, and TSH levels
displayed nonlinear dose-response curves
with a major break in linearity from zero
slope at around the 1,600 ppm dose level.
These data suggested that, if coincident
with tumor incidence data, a benchmark
approach might conceivably be applied
through the most sensitive indicator to
provide a scientific basis for high- to low-
dose extrapolation for secondary thyroid
carcinogenesis.
There is also more detailed information
available on the metabolic pathways and
metabolites ofsuch antithyroid compounds
as methylmercaptoimidazole (MMI) and
PTU (104,105). Some of these data con-
firm the importance of antithyroid drugs
accumulating in the target organ and thus
achieving effective intracellular concentra-
tions at the intrathyroidal site of iodide
organification as a requirement for antithy-
roid activity. Accordingly, it has been cal-
culated that the intracellular concentration
ofPTU in the rat thyroid reaches approxi-
mately 20 pM (106), sufficiently high for
iodination inhibition.
Aparticularlycritical site ofactionrepre-
senting a common intrathyroidal mecha-
nism shared by PTU, ethylenethiourea
(ETU), MMI, and aminotriazole (ATZ) is
TPO inhibition. Antithyroid chemicals
appear to be able to inactivate TPO in one
of two ways, either by a reversible reaction
that does not involve covalent binding, or
by an irreversible interaction involving sui-
cide inactivation ofthe enzyme. The latter
reaction comprises branched pathways that
proceed concurrently-namely, inactivation
of the enzyme and turnover of the suicide
substrate (107). Thus, suicide inhibitors
inactivate TPO by covalent binding to the
prosthetic heme group in the presence of
H202, resulting in H202-dependent cat-
alytic formation of reactive intermediates
(107,108). In this case, de novosynthesis is
required to restore the lost enzyme activity
(109i). The reaction between either PTU or
ETU and the TPO/H202-generating sys-
tem is reversible, representing metabolic
detoxification of these compounds in thy-
roid and not suicide inactivation (107-10,9.
This contrasts with the effects ofMMI and
other thiocarbamide goitrogens, as well as
ATZ, which causesuicide inactivation ofthe
enzyme via covalent binding (107-109).
The difference in action between PTU or
ETU and MMI, involving reversible inhibi-
tion of TPO on the one hand, and irre-
versible inactivation requiring de novo syn-
thesis of enzyme to restore activity on the
other, may account for the longer duration
of effect and greater clinical potency of
MMI (109). The different mechanism of
TPO inactivation between compounds
would not necessarily implicate a different
overall mechanism of rodent thyroid car-
cinogenesis. However, the commonality of
this intrathyroidal mechanism among
antithyroid chemicals that appear to induce
follicular cell carcinogenesis via secondary
effects on the thyroid-pituitary axis suggests
that TPO inactivation might be a useful
additional criterion for categorizing these
chemicals. It has been suggested further
that, for risk assessment purposes, the effect
on TPOprovides abiochemical basis for the
existence of a no observed effect level, or
benchmark ofeffect, in chemically induced
thyroidtoxicity(109).
A marked species difference may exist
between primates and rodents in the inhi-
bition ofTPO by antithyroid compounds.
As examples, inhibition of monkey TPO
requires approximately 50 and 450 times
Volume 106, Number8, August 1998 * Environmental Health PerspectivesReviews * Thyroid regulation and carcinogenesis
the concentration of PTU and sulfa-
monomethoxine, respectively, than does rat
TPO (110). This striking inequality might
explain the greater susceptibility of the rat
to the antithyroid effects of such com-
pounds compared to the primate.
More recent data concerning the
extrathyroidal action of antithyroid com-
pounds on the peripheral conversion ofT4
andT3 involving inhibition ofT4 deiodinas-
es primarily in liver [reviewed by Curran
and De Groot (111)] is available for PTU
(102), ATZ (112), and phenobarbital
(102,113,114). Unlike PTU, ATZ did not
affect the outer ring 5'-deiodination path-
way but stimulated inner-ring 5-deiodina-
tion ofT4, with a consequent increase in
serum concentration ofrT3 (112), an inac-
tive form ofT3. ATZ has no thiocarbonyl
(or aromatic) group in its structure, and the
lack ofsulfur could be an explanation for
the difference in peripheral action from
PTU. The studies with phenobarbital have
confirmed that this drug acts through an
extrathyroidal mechanism by increasing
both hepatic glucuronidation ofT4 as well
as increasing the clearance ofT4 from serum
(102,113,114).These effects were mediated
by the substantial induction of the enzyme
responsible for T4 metabolism, as well as an
increased biliary flow. The effect ofpheno-
barbital solely on the peripheral pathway
and the less potent consequence for thyroid
hormone levels, compared to the effects ofa
centrally acting thiourylene compound like
PTU, accords with its role as a promoter
rather than an inducer of rodent thyroid
tumorigenesis. Recent studies also support a
conclusion that 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD, dioxin) reduces thyroid
hormone levels predominantly by an
extrathyroidal mechanism involving potent
induction ofUDP-GT activity, resulting in
increased hepatic T4 glucuronidation (115).
There is still no epidemiological evidence
that chemicals such as phenobarbital, which
affect thyroid function through a peripheral
mechanism involving thyroid hormone
metabolism, are associatedwith thyroid neo-
plasia in humans (111,116).
In keeping with an indirect action on
TSH hypersecretion from the anterior
pituitary, some antithyroid compounds
have been shown to have central nervous
system effects. Qualitative increases in
TSH-producing thyrotrophs in the rat
pituitary have been associated with admin-
istration of PTU (117) and 4,4'-oxydiani-
line (118), with a rapid reversal ofmorpho-
logic changes upon cessation of treatment
in the case ofPTU. In the PTU study there
was also a coincident decline in growth
hormone cells, suggesting transdifferentia-
tion of somatotrophs into thyrotrophs
(119) and implying changes in cell type
rather than in total cell number in the
hypothyroid state. At the molecular level,
this accords with the induction ofincreased
levels ofTSH mRNA in the anterior pitu-
itary by PTU and a concomitant fall in
growth hormone mRNA (120,121). The
profound effect on cytoplasmic TSH levels
affected both TSH a and 03 subunits in a
dose- and time-dependent manner
(117,120,122), but the increases were rela-
tively greater in TSH P than in the a sub-
unit. T3 replacement reversed these specific
subunit changes (117). These various stud-
ies confirmed a direct influence of"thyroid
status` on the regulation of pituitary hor-
mones at a pretranslational level.
There is evidence that genotoxic chemi-
cals able to induce thyroid cancer in rodents
have different morphological and physiolog-
ical effects from those ofknown goitrogens.
Thus, DHPN induces rat thyroid tumors
along a multistage pathway involving focal
atypical hyperplasia (originating from single
follicles) rather than diffuse follicular hyper-
plasia (123). Furthermore, DHPN and N-
nitrosomethylurea (NMU) do not appear to
influence the thyroid-pituitary axis during
the induction of thyroid carcinogenesis
because these compounds did not increase
thyroid weights unrelated to tumor develop-
ment, cause a persistent elevation of serum
TSH levels, or cause changes in serum T4
levels (124-126).
Collectively, these studies with a range
of compounds strengthen the hypothesis
that antithyroid agents in rodents act by
secondarily causing sustained elevations in
serum TSH levels associated with the
development of thyroid carcinogenesis.
They also highlight the differences in perti-
nent effects between antithyroid com-
pounds and those rodent thyroid carcino-
gens that are directly DNA reactive.
Epidemiology and Etiology of
Human Thyroid Cancer
In humans, tumor histology is important to
the understanding ofthe etiology ofthyroid
cancer because different types appear to rep-
resent separate biological entities with differ-
ent clinical and epidemiological features
(127,128). The most frequent type is papil-
larycarcinoma, accounting for approximately
60% ofall thyroid cancers; follicular carcino-
ma represents about 20% (129). In Sweden,
there are regional differences in the incidence
of papillary and follicular types of thyroid
cancer defined by iodine status, with iodine-
deficient areas being associated with a higher
risk of follicular cancer (128). There is also
some evidence that the incidence rates of
these histological entities may be changing.
The data from one study reflects an increase
for papillary thyroid cancer in Sweden since
1919, but a decline for follicular cancer in
cohorts born since 1939 (127). Although res-
idence in endemic goiter areas in Switzerland
was linked to a modestly increased probabili-
ty ofdeveloping thyroid cancer (130), overall
there remains a general view that no convinc-
ing evidence has yet emerged to linkenviron-
mental thyroid cancer with areas of iodine
deficiency. Furthermore, the long-standing
program of supplementation of food items
with iodine in Sweden has not affected thy-
roid cancer trends in iodine-deficient or
iodine-rich areas (128). Vegetables known to
contain, or endogenously generate, thio-
cyanate have not been found to enhance the
risk of thyroid cancer, but possibly exert a
protective influence (131,132). Ameta-analy-
sis of four similarly designed case-control
dietary studies conducted in high thyroid
cancer areas ofSwitzerland and Italy revealed
an association only with diets rich in starchy
foods and fats, while raw ham and fish were
protective (133).
The onlyverified cause ofthyroid cancer
in humans is exposure to ionizing radiation.
This association has been established for X-
radiation therapy (134-137) andforradioac-
tive fallout (138,139). Of the several events
exemplifying the latter, the Chernobyl
nuclear power plant disaster provides the
most striking correlation. Since 1990, a high
incidence of childhood thyroid cancer has
been recorded in the Republic of Belarus,
affecting predominantly children that were
younger than 1 year old at the time of the
accident (139). Almost all of the cases have
been papillary carcinomas with short latency
(140), in keeping with the observation that
radiation-associated thyroid tumors are pre-
dominantly ofthe papillary type (129). The
most biologically significant isotopes released
in the fallout were radioiodines, primarily
1311, and consequently radioiodine has been
accepted as the causative factor (141). This
stands in marked contrast to the lack ofevi-
dence incriminating diagnostic or therapeu-
tic doses of 1311 (142,143). As with the
Chernobyl experience, age at the time of
treatmentwith X-radiation therapy is also an
important factor in thyroid cancer develop-
ment; the 67-fold risk at 12 years mean age
declines to nonsignificance at a mean age of
29 years (144). In contrast to the risk posed
by high-level ionizing radiation, a well-
designed Chinese study indicates that life-
time exposure to low-level environmental
radiation, with an estimated cumulative dose
of9 cGy, is not a risk factor for human thy-
roid cancer (145).
Graves' disease, an autoimmune thy-
roid condition, is associated with the pres-
ence of circulating antibodies stimulating
the TSH receptor (TSHR Ab) (146,147).
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Whether this disease carries an increased
risk ofthyroid carcinoma has been contro-
versial. Nevertheless, from the collective
published reports, Mazzaferri (148) con-
cluded that thyroid cancer incidence in sur-
gically treated Graves' disease patients is
between 5% and 10%. It is generally
agreed that thyroid cancer occurring in
Graves' disease is an aggressive form (149).
There is strong support for a pathophysio-
logical role ofTSHR Ab rather than circu-
lating TSH in thyroid cancer development
associated with Graves' disease (149,150).
This is because serum TSH levels are sup-
pressed in hyperthyroid patients with thy-
roid cancer, while TSHR Ab's are present
in most cases (149). Evidence that TSHR
Ab are circulating autoantibodies to the
TSH receptor comes from the finding that
they, and monoclonal antibodies to the
human TSH receptor in thyroid tissue,
mimic many of the activities of TSH on
thyroid cells (146,149,151). However, the
role of TSH in mediating the growth of
thyroid nodules in humans needs further
clarification (152).
Changes in Gene Expression
in Thyroid Carcinogenesis
To date, there have been numerous studies at
the molecular level exploring the changes in
gene expression that might accompany
human thyroid carcinogenesis, involving a
wide range of protooncogenes, oncogenes,
tumor-suppressor genes, or gene protein
products. Despite the technical evolution
from transfection methodology topolymerase
chain reaction amplification coupled with
sequence-specific oligonucleotide hybridiza-
tion or probing, some ofthe findings are dis-
cordant. For example, conflicting results have
been obtained for the erbfamily of"nuclear"
oncogenes, and for involvement ofmutations
of the TSH receptor or retinoblastoma (Rb)
gene in thyroid tumor development. Other
investigations have indicated dear evidence of
no role in thyroid cancer for mutation ofthe
APC, plINK4 or nm23 genes, or for abnor-
mal expression ofthe central regulatinggenes,
myc, myb,fos, orjun(2,3,153,154).
There is general agreement emerging
that some of the genetic changes observed
can be correlated with tumor histotype and
stage of tumor development. Point muta-
tions of ras are the most frequent single
genetic abnormalities found in human thy-
roid tumors. Occurring in about 50% of
follicular cell tumors (2,153,154), these
mutations are regarded as early molecular
events in the development ofthis particular
tumor type (155-158). Although all three
rasfamily members have been involved (Ha-
ras, Ki-ras, N-ras), the changes have been
associated mainly with Ha-rasmutation, the
most common mutation site being codon 61
with glutamine to arginine substitution
(156,157,159). When comparing the data
for thyroid cancer associated with areas of
iodine sufficiency, one study found a higher
rate of ras mutation in thyroid tumors from
iodine-deficient areas (157). Also prevalent
in follicular adenomas are gsp mutations. Of
the approximately 20 different Ga subunits
of G proteins, the only one found to be
mutated in thyroid neoplasia has been G5u
(160). This mutation occurs in about 25%
ofcases offollicular adenoma, with a possible
predilection for microfollicular adenomas
(3,154,161,162). Such distribution suggests
that gsp mutation is another early event in
the development offollicular thyroid cancer.
However, there are some discrepancies
between studies concerning the involvement
ofG proteins in thyroid neoplasia (163), and
mutations in GSa have been found in only a
minorityoftoxic thyroid adenomas (164).
In contrast to follicular tumors, an
absence of ras and Gsa gene mutations has
been recorded for papillary thyroid cancer
(165-166). Instead, rearrangements of ret
and trk, protooncogenes ofthe tyrosine pro-
tein kinase receptor family, are early events
associated with the papillary type of cancer
(158). The redPTC rearrangement is specific
for the thyroid and is found in up to 30% of
human papillary carcinomas (154,167,168).
As this alteration has been detected in more
than 40% of occult papillary carcinomas,
generally considered to be the incipient stage
ofpapillary malignancy, it is believed to rep-
resent an early event in the development of
this tumor histotype (168). A higher preva-
lence of retprotooncogene rearrangement, in
up to two- thirds of cases, has now been
recorded in papillary thyroid carcinomas
from children exposed to the Chernobyl
nuclear reactor accident (169-171). Unlike
the situation in adult tumors and those asso-
ciated with therapeutic irradiation (172),
where the most common ret translocation is
retIPTC1, the alteration in the childhood
radiation tumors from Belarus has been pref-
erentially retIPTC3 (ELE/RE7) rearrange-
ment (169-171), with several aberrant forms
offusion being described (173). Interestingly,
the only reproducible cytogenetic abnormali-
ty found in papillary thyroid cancer has been
an inversion of chromosome 10 at the
10qI 1.2 locus, which is known to involve the
retprotoocogene at that locus (174,175). As
one possible mechanism linking these
changes with neoplastic transformation,
expression of the retIPTCI oncogene has
been shown to impair the activity of certain
transcription factors involved in regulating
differentiated functions ofthyroid cells (176).
Activating rearrangement ofthe trkprotooco-
gene has also been found only in papillary
carcinomas (153,154); overexpression of the
metoncogene is another molecular aberration
observed mainly in this tumor histotype
(3,154).
Little is known concerning molecular
changes involved in the transition from fol-
licular cell adenoma to carcinoma, although
a loss of heterozygosity involving chromo-
some 3p was considered to bespecific for fol-
licular carcinoma, appearing to correlate with
the transition from the adenoma to the carci-
noma stage (177,178). Chromosomal analy-
sis offollicular thyroid tumors has also indi-
cated the existence of three cytogenetically
distinct subsets ofadenoma, with numerical
changes in chromosomes 5, 7, and 12 as the
most frequent cluster ofanomalies (179). A
similar cluster of alterations found in some
thyroid nodular hyperplasias has been inter-
preted as support for a biologic continuum
between hyperplastic nodules and the most
common subset of adenomas (180). At the
histological level, polysomies for chromo-
somes 7 and/or 12 have been observed only
in lesions with an exclusive or predominant
microfollicular component (181). There is
some evidence from several studies that
mutation of the tumor-suppressor gene p53
is a late genetic event in thyroid carcinogene-
sis involved in the progression to a more
aggressive phenotype in the form ofundiffer-
entiated or anaplastic cancer (165,182,183).
In vitro data suggest that progression to the
anaplastic phenotype involves cooperative
events ofp53 mutation together with dedif-
ferentiation, an epigenetic event (158).
The role of TSH receptor gene muta-
tions in the development of thyroid cancer
is uncertain. Russo et al. (184) found acti-
vating mutations in the third intracellular
loop ofthe TSH receptor in halfofdifferen-
tiated thyroid carcinomas constitutively
expressing high adenylate cyclase activity.
Other studies have found infrequent
involvement of such genetic changes in
malignant transformation of the thyroid,
leading to the conclusion that mutational
activation of intracellular domains of the
TSH receptor is not an important mecha-
nism ofthyroid tumorigenesis (185,186). In
contrast, somatic mutations of the TSH
receptor gene are considered to be the most
frequent cause of toxic thyroid adenomas,
autonomous, frequently self-limiting, hyper-
functioning nodules that are not dependent
on TSH (164,187). When introduced and
expressed in thyroid cells, these mutations
are able to confer TSH-independent
growth, providing a specific molecular link
between TSH receptor mutations and toxic
adenomas (188). The majority oftoxic ade-
nomas with constitutively activating TSH
receptor mutations appear to result from
clonal expansion ofa single cell (18Th.
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Genetic alterations have also been
detected in rat thyroid carcinogenesis, but
only a few investigations have been reported.
Ha-rasactivation was exclusively involved in
a majority oftumors induced by the direct-
acting genotoxin NMU (190). In DHPN-
induced rat thyroid tumors, however, muta-
tions involved the Ki-ras gene via a G to A
transition at the second base of codon 12
(191). The same point mutation was detect-
ed at an early time point in preneoplastic
thyroid, suggesting that Ki-ras mutations
may play a role in the development of
DHPN-induced rodent thyroid cancer. In
about half of cases, radiation-induced thy-
roid tumors in rats were associated preferen-
tially with Ki-ras activation (190). In this
respect the rat data conform with that for
radiation-induced papillary thyroid tumors
in humans, which also are associated with
Ki-ras mutation (192). On the other hand,
ATZ-induced adenomas in the rat showed
only a low incidence of Ki-ras activation
(190). In studies using a series of trans-
plantable rat thyroid carcinoma cell lines
induced by DHPN, Kitahori et al. (193)
confirmed the activation of the Ki-ras gene
as a frequent event but also found a point
mutation of Gsa in several lines. Point
mutations in the Gsa gene, fixing the GSx
protein in its active state, inhibit GTPase
activity, thus increasing intracellular cAMP
levels via stimulation ofadenylate cyclase. In
the same study, a point mutation in the
intracellular domain of the TSH receptor
gene was found in only one cell line, and
there was an absence ofp53 mutations. The
authors concluded that G to A point muta-
tions in Gsa and ras genes directly reflected
interaction of the carcinogenic nitrosamine
with guanine residues in DNA (193).
Data Gaps and Research
Needs
Much of the recent new data strengthen
the hypothesis that nongenotoxic, antithy-
roid compounds induce rodent thyroid fol-
licular cell carcinogenesis by an indirect
mechanism involving thyroid-pituitary
feedback regulation, and none of the data
negate that notion. Some of the new evi-
dence also supports the view that humans
may be less sensitive to the antithyroid
process than rodents. Nevertheless, there
are gaps in the available information that
require further research, as listed below.
* Despite the voluminous literature on thy-
roid autoregulation, more research is
needed before the complex interactive
network is fully elucidated.
*More data are required to clarify the role
and interaction of oncogene mutations
and growth factor alterations in thyroid
carcinogenesis in both rodent and
human, and particularly in defining dif-
ferences, if any, between rodent thyroid
cancer induced by antithyroid com-
pounds compared to the action of geno-
toxic carcinogens.
*The differences that might distinguish
the thyroid-related mechanisms ofaction
of antithyroid compounds versus geno-
toxic carcinogens, such as DNA adduct
analysis within the thyroid, and the
effects of DNA-reactive carcinogens on
TPO, require elucidation.
*More information is required directly
linking persistently high levels ofcirculat-
ing TSH with a step-by-step sequence
involved in the cellular development of
thyroid follicular cell neoplasia.
*Well-conducted studies are needed to
better define the comparative sensitivity
of humans, relative to rodents, to the
long-term effects ofantithyroid factors.
*Using analytical epidemiology tech-
niques, the environmental and dietary
risk factors for thyroid cancer based on
histological type in various human popu-
lations need to be better defined.
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